PMID- 36870951 OWN - NLM STAT- MEDLINE DCOM- 20230307 LR - 20230307 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Mar 4 TI - Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy. PG - 206 LID - 10.1186/s12885-023-10676-x [doi] LID - 206 AB - OBJECTIVES: Central nervous system (CNS) metastases including brain metastases (BM) and leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), and are correlated with poor outcomes. In this study, we evaluated the efficacy of single-agent furmonertinib 160 mg or combining with anti-angiogenic agent in NSCLC patients who had developed BM/LM progression from previous tyrosine kinase inhibior (TKI) treatment. METHODS: EGFR-mutated NSCLC patients who developed BM (the BM cohort) or LM progression (the LM cohort) were included, having received furmonertinib 160 mg daily as second-line or later treatment, with or without anti-angiogenic agents. The intracranial efficacy was evaluated by intracranial progression-free survival (iPFS). RESULTS: Totally 12 patients in the BM cohort and 16 patients in the LM cohort were included. Almost one half of patients in the BM cohort and a majority in the LM cohort had a poor physical status, with a Eastern Cooperative Oncology Group performance status (ECOG-PS) >/=2. The administration of single-agent furmonertinib or combination treatment achieved a median iPFS of 3.6 months (95%CI 1.435-5.705) in the BM cohort, and 4.3 months (95%CI 2.094-6.486) in the LM cohort. Subgroup and univariate analysis has shown that a good ECOG-PS correlated with a favorable efficacy of furmonertinib in the BM cohort (median iPFS = 2.1 with ECOG-PS >/= 2 vs. 14.6 months with ECOG-PS < 2, P < 0.05). Overall, any grade of adverse events (AEs) occured in 46.4% of patients (13/28). Among them, 14.3% of patients (4 of 28) had grade 3 or higher AEs, and were all under control, led to no dose reductions or suspension. CONCLUSION: Single-agent furmonertinib 160 mg or in combination of anti-angiogenic agent is an optional salvage therapy for advanced NSCLC patients who developed BM/LM progression from prior EGFR-TKI treatment, with a promising efficacy and an acceptable safety profile, and is worth of further exploration. CI - (c) 2023. The Author(s). FAU - Xu, Ziyi AU - Xu Z AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Hao, Xuezhi AU - Hao X AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Wang, Qi AU - Wang Q AD - Department of Medical Oncology, Beijing Chaoyang Sanhuan Hospital, Beijing, 100021, China. FAU - Yang, Ke AU - Yang K AD - Department of Medical Oncology, Cancer Hospital of Huanxing, Beijing, 100021, China. FAU - Li, Junling AU - Li J AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. lijunling@cicams.ac.cn. FAU - Xing, Puyuan AU - Xing P AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. xingpuyuan@cicams.ac.cn. LA - eng PT - Journal Article DEP - 20230304 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - A49A7A5YN4 (aflutinib) RN - 0 (Angiogenesis Inhibitors) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Humans MH - Salvage Therapy MH - *Carcinoma, Non-Small-Cell Lung MH - *Lung Neoplasms MH - *Brain Neoplasms MH - Angiogenesis Inhibitors MH - ErbB Receptors MH - *Meningeal Carcinomatosis MH - *Neoplasms, Second Primary PMC - PMC9985196 OTO - NOTNLM OT - Anti-angiogenic agent OT - BM/LM OT - EGFR-mutated NSCLC OT - Furmonertinib OT - Salvage therapy COIS- The authors declare no competing interests. EDAT- 2023/03/05 06:00 MHDA- 2023/03/08 06:00 PMCR- 2023/03/04 CRDT- 2023/03/04 23:32 PHST- 2022/11/18 00:00 [received] PHST- 2023/02/24 00:00 [accepted] PHST- 2023/03/04 23:32 [entrez] PHST- 2023/03/05 06:00 [pubmed] PHST- 2023/03/08 06:00 [medline] PHST- 2023/03/04 00:00 [pmc-release] AID - 10.1186/s12885-023-10676-x [pii] AID - 10676 [pii] AID - 10.1186/s12885-023-10676-x [doi] PST - epublish SO - BMC Cancer. 2023 Mar 4;23(1):206. doi: 10.1186/s12885-023-10676-x.